Karamvir Yadav, Medical Oncologist in Jaipur, India, shared a post on X:
“Can cfDNA fragmentomics transform breast cancer detection?
Multicenter study (Nature Communications 2026) shows: Early detection sensitivity 95% Molecular subtype prediction from blood Lymph node metastasis prediction NPV 97.6%.
One blood test – Detection + Subtyping + Nodal assessment.
Title: Fragmentomic liquid biopsy enables early breast cancer detection, molecular subtyping and lymph node assessment
Authors: Yuxuan Zhu, Siwei Zheng, Yinkuan Shao, Jun Zhou, Xidong Gu, Lesang Shen, Xue Li, Wenjia Liu, Wei Xue, Haiqi Lu, Jun Zhou, Jinghua Ding, Haiming Deng, Jiayin Chen, Zhuohang Yu, Yao Yao, Wenjie Xia, Wuzhen Chen, Shanshan Sun, Zheng Wang, Tianyi Qian, Xiuyan Yu, Jian Liu, Yiding Chen, Ziao Lin, Jian Huang, Chao Ni
Read The Full Article
Nice informative article Journal of Clinical Oncology.
Thromboembolism in cancer trials may be significantly underestimated. RCTs: VTE often <3% Real-world: >10% Better reporting of VTE and ATE, longer follow-up, and real-world data are critical to improve patient safety and prevention.
Title: Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action
Authors: David C. Calverley, Avi Leader, May Anne Cheong, Kristen M. Sanfilippo, Ginny Mason, Gary H. Lyman, Nicole M. Kuderer
Read The Full Article
Obesity is reshaping the cancer landscape.
- ≥13 obesity-associated cancers.
- ~10% of cancers linked to excess adiposity.
- Mechanisms: metabolic dysregulation, chronic inflammation, hormonal signaling Prevention opportunity: weight loss, lifestyle change, metabolic therapies.”
Title: Obesity and Cancer: A Translational Science Review
Authors: Sherry Shen, Kristy A. Brown, Angela K. Green, Neil M. Iyengar
Read The Full Article
Other articles about cfDNA on OncoDaily.